Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...